RxDoctor Payments Data

Ayodele Ayoola, MD

Internal Medicine · Hershey, PANPI 1164558763

Payments from drug & device makers

$141,714in general payments, 2019–2025

Across 375 payments — averaging $377.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Taiho Oncology, Inc.$39K
  • E.r. Squibb & Sons, L.L.C.$35K
  • Novartis$23K
  • Bristol Myers Squibb$12K
  • Jazz Pharmaceuticals Inc.$7K
  • AstraZeneca$7K
  • plus $18K from 42 others

What the payments were for

  • Consulting fees$17,87813%
  • Speaking & faculty fees$88,08362%
  • Travel & lodging$21,21315%
  • Food & beverage$12,3249%
  • Education$2,2162%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,714 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,178
Medicare patients
325
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate38$599,939
KisqaliRibociclib Succinate28$486,342
ErleadaApalutamide27$454,136
NubeqaDarolutamide24$320,178
InrebicFedratinib Dihydrochloride12$318,543
CabometyxCabozantinib S-Malate11$271,299
LonsurfTrifluridine/Tipiracil Hcl15$267,885
PomalystPomalidomide11$251,317
JakafiRuxolitinib Phosphate13$229,583
RevlimidLenalidomide13$229,558
Abiraterone Acetate64$212,676
BesremiRopeginterferon Alfa-2b-Njft11$178,354
BrukinsaZanubrutinib11$160,869
VenclextaVenetoclax26$89,107
Everolimus13$38,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$6,881$599,93938 claims
Bristol Myers SquibbInrebic, Revlimid$12,111$548,10125 claims
NovartisKisqali$23,006$486,34228 claims
Johnson & JohnsonErleada, Xarelto$665$467,05740 claims
BayerNubeqa$1,658$320,17824 claims
Exelixis Inc.Cabometyx$2,939$271,29911 claims
Taiho Oncology, Inc.Lonsurf$39,457$267,88515 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$35,072$251,31711 claims
Incyte CorporationJakafi$215$229,58313 claims
Beigene USA, Inc.Brukinsa$124$160,86911 claims
AbbVieVenclexta$286$89,10726 claims
PfizerEliquis$1,413$18,50123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →